Sep 13, 2022 Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal Learn More
May 10, 2022 Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update Learn More